4RD Stock Overview
MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
MaaT Pharma SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €8.94 |
| 52 Week High | €9.22 |
| 52 Week Low | €4.78 |
| Beta | 0.22 |
| 1 Month Change | -1.97% |
| 3 Month Change | 31.86% |
| 1 Year Change | 8.23% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -30.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4RD | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.8% | -0.7% | 2.5% |
| 1Y | 8.2% | -21.2% | 5.4% |
Return vs Industry: 4RD exceeded the German Biotechs industry which returned -21.2% over the past year.
Return vs Market: 4RD exceeded the German Market which returned 5.4% over the past year.
Price Volatility
| 4RD volatility | |
|---|---|
| 4RD Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4RD's share price has been volatile over the past 3 months.
Volatility Over Time: 4RD's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 56 | Herve Affagard | www.maatpharma.com |
MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.
MaaT Pharma SA Fundamentals Summary
| 4RD fundamental statistics | |
|---|---|
| Market cap | €109.76m |
| Earnings (TTM) | -€19.72m |
| Revenue (TTM) | €2.23m |
49.3x
P/S Ratio-5.6x
P/E RatioIs 4RD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4RD income statement (TTM) | |
|---|---|
| Revenue | €2.23m |
| Cost of Revenue | €878.00k |
| Gross Profit | €1.35m |
| Other Expenses | €21.07m |
| Earnings | -€19.72m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | -1.70 |
| Gross Margin | 60.59% |
| Net Profit Margin | -884.96% |
| Debt/Equity Ratio | 38.9% |
How did 4RD perform over the long term?
See historical performance and comparison